Aalto Bio Reagents Features in Country Reports Article for its Rapid Response to the COVID-19 Crisis
Updated: Jun 15
Dublin, Ireland - 14th June 2021 (Newsweek.com) - One of the oldest privately held biotech companies present in Ireland is Aalto Bio Reagents, the market leader in the development of proteins and antibodies for new and emerging diseases. In addition to being Europe’s largest provider of bulk disease state plasma for controls, the firm is a major custom manufacturer of new recombinant antigens, while its strong product portfolio includes bulk antigens and antibodies. Pre-COVID-19, much of its work was concentrated on tackling serious tropical diseases, but it has now grown into a leading developer of critical raw materials and reagents for the development of diagnostic tests.
“If there is a new disease, we find the solution early,” states CEO Philip Noone. “We are finding that solution first, we are finding it early and we are going to solve the problems of the world in terms of touching hundreds of millions of people’s lives by being able to diagnose diseases earlier and faster than anybody else. Through the COVID-19 experience, we have been able to shorten the development process from 15 months to within two months. We have now fine-tuned our internal processes so that we can build it a lot quicker. A lot of the rapid COVID-19 tests on the market have Aalto-based proteins in them to do that diagnosis.”
Noone believes that life science, as a business, is extremely robust, as evidenced by Aalto’s continued operation and solid production throughout the current pandemic. “We are going to continue to grow, expand and add very innovative products that nobody else has in the market and try to be first with those products,” he pledges.
See the full article on NEWSWEEK.com below.
About Aalto Bio Reagents:
Founded in 1978, Aalto Bio Reagents is a leading developer and provider of raw materials to the in-vitro diagnostics industry and to research laboratories globally. We serve the largest multinational companies in our industry with a broad range of purified human proteins; monoclonal and polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; and disease state plasma for in-vitro diagnostic application.
Since the company's inception, we have built strong working relationships with our clients who trust us to provide them with the highest quality raw materials to meet the exacting standards of their own product development requirements. Headquartered in Dublin, Ireland, the company is rapidly expanding both its product portfolio and customer base. For further information please visit http://www.aaltobioreagents.com
Contact Aalto Bio Reagents: